|TUESDAY, MARCH 28|
|11:25 am - 12:25 pm
Mile High 4A-4C
| Amgen, Inc.
What drives the differences in value conclusions? A health-economic case study on cardiovascular outcome data
In the US there is an increasing interest in value and cost effectiveness. However, it is not uncommon for different researchers to make contrary conclusions on the value of a product. While there are multiple assumptions that could potentially impact the value assessment, two key drivers will be identified and discussed in the context of cardiovascular disease. In addition, with the recent release of the first cardiovascular outcome on a PCSK9 inhibitor at ACC, those concepts will be illustrated via a case study. Overall, the workshop aims to foster a better understanding of cost effectiveness analyses and assist formulary, coverage and reimbursement decision makers in critical evaluation of a product's value.
This workshop is intended for formulary, coverage and reimbursement decision makers only.
Ransi Somaratne, MD, FACC
Executive Medical Director
Clifford Goodman, PhD
Senior Vice President
The Lewin Group
Falls Church, VA
Tanya GK Bentley, PhD
Senior Director, Health Economics
Partnership for Health Analytic Research, LLC
Beverly Hills, CA
Click Here to Register
|11:25 am - 12:25 pm
Mile High 1A-1C
SPINRAZA™ (nusinersen) Clinical Overview
SPINRAZA was approved by the FDA in December 2016. Biogen invites you to join us for a non-CME presentation by Nancy L. Kuntz, MD, Attending Neurologist at the Ann & Robert H. Lurie Children’s Hospital of Chicago and an investigator for the SPINRAZA clinical trials, for an in-depth clinical review of SPINRAZA.
The program will highlight the clinical profile of SPINRAZA, including efficacy and safety data. In addition, the presentation will discuss other relevant information regarding SPINRAZA, including an overview of the clinical study designs, efficacy results, adverse events, dosing and administration, and mechanism of action.
Join us as we share an educational clinical overview of SPINRAZA.
Nancy L Kuntz, MD
Attending Neurologist, Ann & Robert H. Lurie Children’s Hospital of Chicago
Medical Director, Mazza Foundation Neuromuscular Disorders Program
MDA Clinic Director, MDA Clinic at Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine
|7:30 pm – 8:30 pm
Mile High 4A-4C
Real-world Insights & Economic Considerations in Type 2 Diabetes: The Challenge of Sustaining Glycemic Control & Medication Adherence Over Time
Large claims databases offer a unique opportunity to examine year-to-year trends in diabetes population management. Intarcia Therapeutics, Inc., sponsored a study conducted by Milliman, a well-known source of actuarial expertise to the healthcare industry, to develop a white paper titled Real-world Insights & Economic Considerations in Type 2 Diabetes, which highlights the relationship between glycemic control and medication adherence.
Key topics of the discussion will include:
• Trends in HbA1c and diabetes drug adherence
• Challenge of sustaining glycemic control and diabetes drug adherence over time
• Association between healthcare costs and HbA1c levels
• Correlation between glycemic control and medication adherence, including drug therapy characteristics
In addition to the presentation by a Milliman consultant, an endocrinologist will discuss the challenges confronting clinicians in optimally managing a progressive chronic disease, such as type 2 diabetes, as well as the struggles patients face in adhering to their diabetes medication regimen.
Principal, Healthcare Management Consultant
Kristina Yu-Isenberg, PhD, MPH, RPh
Vice President and Head of Evidence Generation & Analytics, Global Medical Affairs
Jay S. Skyler, MD, MACP
Professor of Medicine, Pediatrics, and Psychology in the Division of Endocrinology, Diabetes, and Metabolism
University of Miami
No Fee Registration: Click Here
© 2017 Academy of Managed Care Pharmacy | 675 North Washington Street, Suite 220, Alexandria, VA 22314 | 703-684-2600 | email@example.com